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The ever increasing multidrug-resistance of clinically important pathogens and the lack
of novel antibiotics have resulted in a true antibiotic crisis where many antibiotics are no
longer effective. Further complicating the treatment of bacterial infections are antibiotic-
tolerant persister cells. Besides being responsible for the recalcitrant nature of chronic
infections, persister cells greatly contribute to the observed antibiotic tolerance in
biofilms and even facilitate the emergence of antibiotic resistance. Evidently, eradication
of these persister cells could greatly improve patient outcomes and targeting persistence
may provide an alternative approach in combatting chronic infections. We recently
characterized 1-((2,4-dichlorophenethyl)amino)-3-phenoxypropan-2-ol (SPI009), a novel
anti-persister molecule capable of directly killing persisters from both Gram-negative and
Gram-positive pathogens. SPI009 potentiates antibiotic activity in several in vitro and
in vivo infection models and possesses promising anti-biofilm activity. Strikingly, SPI009
restores antibiotic sensitivity even in resistant strains. In this study, we investigated
the mode of action of this novel compound using several parallel approaches.
Genetic analyses and a macromolecular synthesis assays suggest that SPI009 acts
by causing extensive membrane damage. This hypothesis was confirmed by liposome
leakage assay and membrane permeability studies, demonstrating that SPI009 rapidly
impairs the bacterial outer and inner membranes. Evaluation of SPI009-resistant
mutants, which only could be generated under severe selection pressure, suggested
a possible role for the MexCD-OprJ efflux pump. Overall, our results demonstrate the
extensive membrane-damaging activity of SPI009 and confirm its clinical potential in the
development of novel anti-persister therapies.
Keywords: Pseudomonas aeruginosa, mechanism of action studies, membrane damage, antibiotic tolerance,
anti-persister therapies
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INTRODUCTION
Modifying existing antibiotic scaffolds upon emergence of
resistance has proven a successful strategy to extend a drug
class’ utility in the past. However, recent data suggest that
multidrug-resistance increases at an alarming rate while
few novel antibacterials reach the market (Wright, 2014;
O’Neill, 2015). A particular issue are multidrug-resistant
Gram-negative pathogens such as Pseudomonas aeruginosa,
posing additional challenges to antibiotic discovery due
to their highly impermeable outer membrane (Livermore,
2002; Breidenstein et al., 2011), and the so-called ESKAPE
pathogens (Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumannii, P. aeruginosa,
and Enterobacter spp.), efficiently evading antibiotic treatment
and responsible for the majority of bacterial infections (Rice,
2008; Delcour, 2009; Poole, 2011). Since no new antibiotic
scaffolds active against Gram-negative pathogens have been
identified in the last decades, physicians are reverting to the use
of polymyxins, once avoided due to toxic effects, as a last-resort
treatment for these strains. Therefore, new antibacterial scaffolds
are desperately needed (Falagas and Kasiakou, 2005; Walsh and
Wencewicz, 2014).
Contributing to the difficult treatment of bacterial infections
is the presence of persister cells which constitute a small
but important fraction of phenotypic variants tolerant to
treatment with high doses of antibiotics (Lewis, 2010). Their
occurrence in many bacterial pathogens combined with a
demonstrated link between persistence and the recalcitrant
nature of chronic bacterial infections renders persisters a
serious threat to immunocompromised patients and effective
anti-persister treatments are much needed (Fauvart et al., 2011;
Zhang, 2014; Fisher et al., 2017). Previous research revealed the
strong antibacterial effect of the novel anti-persister molecule
SPI009 (Liebens et al., 2017; Figure 1) as an adjuvant in
combination therapies against different bacterial pathogens.
In addition, the compound proved highly successful in the
treatment of intracellular and in vivo P. aeruginosa infections
when combined with the fluoroquinolone ciprofloxacin. SPI009
sensitizes bacteria to antibiotic activity and, strikingly, restores
antibiotic sensitivity even in resistant strains. In addition, SPI009
monotherapy exhibited extensive inhibition and eradication
activity in biofilms of P. aeruginosa and S. aureus (Defraine et al.,
2017). The current need for novel antibacterials active against
Gram-negative species, together with the unique characteristic
of SPI009 to kill both normal and persister cells, prompted us to
further investigate the mode of action of this compound.
Current approaches to identify the next generation of
antibacterials involve high-throughput screenings of natural and
chemical products, the characterization and adaptation of new
antibacterial structures (Samanta et al., 2013; Mandal et al., 2017),
genome hunting, whole-cell-based assays and the targeting of
non-multiplying bacteria (Coates et al., 2002). As these options
offer interesting alternatives that can bypass the identification
of novel antibiotic targets, mechanism of action studies become
increasingly important to characterize and select interesting
candidates after initial discovery (Terstappen et al., 2007).
FIGURE 1 | Chemical structure of the propanol-amine derivative
1-((2,4-dichlorophenethyl)amino)-3-phenoxypropan-2-ol (SPI009).
In this study, we set out to determine the mode of
action of a recently discovered antibacterial compound, SPI009,
showing a broad spectrum antibacterial effect and capable
of killing both dividing cells and non-dividing or dormant
persister cells (Liebens et al., 2017). While generating useful
information for the further development of this compound as an
antibacterial therapy, determination of the mode of action could
also greatly assist in the development of future anti-persister
therapies. A combination of genetic and cellular approaches
was employed, revealing the membrane damaging activity of
SPI009 and suggesting the ability of SPI009 to attack the
bacterial membrane(s) both from the cytoplasm and extracellular
environment.
MATERIALS AND METHODS
Bacterial Strains, Media, and Growth
Conditions
Bacterial strains were cultured in 1:20 diluted trypticase soy broth
(1:20 TSB) at 37◦C, shaking at 200 rpm. For solid medium, TSB
was supplemented with 1.5% agar. The following antibacterials
were used: ofloxacin, ciprofloxacin, erythromycin, polymyxin
B, rifampicin (Sigma – Aldrich), fosfomycin, meropenem (TCI
Europe), triclosan (Merck Chemicals), melittin (Bachem), and
SPI009 (Figure 1). Concentrations are indicated throughout the
text. Bacterial strains used in this study are listed in Table 1.
Screening of a P. aeruginosa Mutant
Library
A genetic screen of the P. aeruginosa PA14 transposon mutant
library (Liberati et al., 2006) was performed to identify single
gene knockouts sensitive or resistant for SPI009. Stationary
phase mutant cultures were split in two and treated for 5 h
with either 10 µg/mL ofloxacin or the combination of ofloxacin
and 51 µg/mL of SPI009. Treated cultures were diluted 1:100
in fresh TSB medium and incubated at 37◦C, shaking at
200 rpm. Growth was monitored over a total period of 40 h by
means of periodic OD595 measurements. Average OD595 was
calculated for each 96-well plate and used to correct mutant
OD595 values. Mutants were identified as sensitive if the OD595
after 24 h of growth was ≤0.3× average OD595 after 24 h.
Alternatively, mutants having an OD595 >3× average were
defined as resistant. The screening was performed twice to
prevent false-positive hits and, to allow identification of SPI009
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TABLE 1 | Strains used in this study.
Strain Description Source or reference
Pseudomonas aeruginosa
PA14 WT Wild type
UCBPP–PA14
Pierre Cornelis;
Lee et al., 2006
YM WT PAO1 WT, K767 De Kievit et al., 2001
YM64 mexAB-oprM::FRT,
mexXY::FRT,
mexCD-oprJ::FRT,
mexEF-oprN::FRT
Morita et al., 2001
K1521 K767 1mexCD-oprJ De Kievit et al., 2001
K1525 K767 1mexXY De Kievit et al., 2001
Liberati WT Wild type UCBPP-PA14
(Lib WT)
Liberati et al., 2006
1galU PA14_38350::Mar2xT7
(52640)
Liberati et al., 2006
1nfxB PA14_60860::Mar2xT7
(55219)
Liberati et al., 2006
1PA14_0812 PA14_08120::Mar2xT7
(47659)
Liberati et al., 2006
Acinetobacter baumannii
Ab-84 MDR clinical isolate García-Quintanilla et al., 2014
Ab-84R Ab-84::40nt insertion at
nt 321 of lpxC
García-Quintanilla et al., 2014
specific effects, selected mutants showing a clear sensitivity
or resistance for ofloxacin were excluded. Resistant hits were
additionally confirmed via detailed monitoring of growth in the
presence of 51 µg/mL SPI009, using an automated OD reader
(Bioscreen C). Functional enrichment analysis was performed
based on PseudoCAP classifications and using Fisher’s exact test.
A schematic overview of the described workflow can be found in
Supplementary Figure S1.
RNA Sequencing and Data Analysis
Overnight cultures of P. aeruginosa were diluted 1:100 in fresh
1/20 TSB medium and allowed to grow until late-exponential
phase (OD595 = 0.2). Cells were treated for 15 min with 50 µM
SPI009, 50 µM of the inactive analog SPI014 or 1% DMSO.
Total RNA isolation was performed in triplicate for each sample,
as previously described (Liebens et al., 2014). The Ribo-ZeroTM
rRNA Removal Kit for Gram-negative bacteria (Epicentre) was
used to deplete ribosomal RNA and RNA samples were sent
to the Genomics Core facility of EMBL (Heidelberg, Germany).
The quality of the raw sequencing reads was verified using
FastQC after which genomic alignments of the reads were
performed with Bowtie2, using the P. aeruginosa UCBPP-PA14
genome as a reference (NC_008463.1). Differential expression
analysis between treated and control samples was done using
the DESeq2 package with a False Discovery Rate threshold of
5% (Love et al., 2014). Genes with a log2 fold-change above
1 and no differential expression under the inactive compound
treatment were selected, allowing the detection of SPI009
specific effects on gene expression. Functional annotation of the
obtained results was performed using PseudoCAP functional
classes obtained from www.pseudomonas.com (Winsor et al.,
2016) and functional enrichment was assessed using Fisher’s
exact test. A UCBPP-PA14 interaction network was created
using the STRING database (Szklarczyk et al., 2011) where
only reactions with a minimum reliability score of 0.8 were
retained. PheNetic was run using both this network and the
obtained omics data to generate a downstream interaction
network, using the standard parameters and a cost of 0.25
(De Maeyer et al., 2013). Obtained networks containing more
than two genes were visualized using Cytoscape (Shannon et al.,
2003).
Macromolecular Synthesis Assay
An overnight culture of P. aeruginosa PA14 wild type
(WT) was diluted 1:10 in 1/20 TSB and grown to an
OD600 of 0.3 at 37◦C (late exponential phase). Radiolabeled
precursors for DNA (1 µCi/mL [methyl-3H]-thymidine), RNA
(2.5 µCi/mL [5,6-3H]-uridine), protein (2.5 µCi/mL L-[4,5-3H]-
leucine), peptidoglycan (2.5 µCi/mL D-[6-3H(N)]-glucosamine
hydrochloride), and fatty acids (1 µCi/mL [2-3H]-glycerol) were
added after which cultures were treated with 17 µg/mL SPI009
or 8×MIC concentrations of relevant control antibiotics. Thirty
minutes after onset of treatment, 100 µL samples were added
to 3.5 mL of ice-cold 10% TCA and precipitates were collected
under vacuum on 25 mm glass microfiber filters (Whatman R©
Grade GF/C). Filters were washed twice with 4 mL ice-cold
distilled water and added to 3.5 mL scintillation liquid (Ultima-
Flo M, PerkinElmer). Incorporation of the different radiolabels
was assessed using a Hidex 300SL scintillation counter. Counts
per minute at different treatment conditions were used to
evaluate the incorporation of radiolabeled precursors relative to
the untreated control, as previously described (Cotsonas King
and Wu, 2009; Grzegorzewicz et al., 2012; Nowakowska et al.,
2013; Ling et al., 2015).
Fluorescein Leakage Assay
Small unilamellar vesicles (SUVs) representing the Gram-
negative membrane and loaded with carboxyfluorescein
(CF) were produced as described previously (Randall
et al., 2013; Gerits et al., 2016). The total phospholipid
concentration was kept at 25 µM, containing a mixture of
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)/1,2-
dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DOPG) (4:1)
(Avanti Polar Lipids, Inc). Liposomes were treated with
increasing concentrations of SPI009 and an inactive chemical
analog, SPI023, keeping the final DMSO concentration at
1% (v:v). Release of CF (λex = 485 nm, λem = 520 nm) was
measured in function of time. The percentage of CF leakage was
determined relative to the treatment with 0.5% Triton X-100.
Assessment of Inner and Outer
Membrane Permeabilization
Inner membrane permeabilization was examined using a SYTOX
Green uptake assay, as previously described (Gerits et al., 2016).
A PA14 WT culture was grown until late exponential phase and
corrected to a final OD595 of 0.5 in 1× phosphate-buffered
saline supplemented with 1 µM SYTOX Green. Cultures were
treated with Milli-Q (MQ; untreated control), DMSO (1%;
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carrier control), 10 µg/mL melittin (1× MIC) and increasing
concentrations of SPI009 and transferred to the wells of a black
microtiter plate (clear bottom). Fluorescence (λex = 504 nm,
λem = 523) and absorbance (OD595) were measured every
minute, using a Synergy MX multimode reader (BioTek) at 37◦C.
Pseudomonas aeruginosa outer membrane permeabilization
by SPI009 was measured using a 1-N-phenylnaphthylamine
(NPN, Sigma, United States) uptake assay (Gerits et al., 2016).
Briefly, a P. aeruginosa PA14 WT culture was grown until late
exponential phase, after which the OD595 was corrected to 0.5 in
5 mM HEPES (pH = 7.2). A total of 150 µL volumes of culture
were treated with MQ (untreated control), DMSO (1%; carrier
control), 0.625 µg/mL polymyxin B (1× MIC) and different
concentrations of SPI009 (4.25–34 µg/mL) and transferred to the
wells of a black microtiter plate (clear bottom). Fifty microliters
of a 40 µM NPN solution in 5 mM HEPES (pH = 7.2) was added
and fluorescence was measured immediately using a Synergy MX
multimode reader (BioTek) at 37◦C.
Independent assays for outer and inner membrane
permeabilization assessment were performed three times.
Measured fluorescence signals were divided by well-specific
OD595 to correct for cell density after which the values of
the respective untreated controls were subtracted. Results are
expressed in relative fluorescence units.
Microscopic Confirmation of Membrane
Damage
Overnight cultures of P. aeruginosa and S. aureus were
treated for 20 min with 0.5% DMSO (carrier control)
or 34 µg/mL SPI009, centrifuged and stained with
10 µg/mL N-(3-triethylammoniumpropyl)-4-(6-(4-(diethyl
amino)phenyl)hexatrienyl)pyridinium dibromide (FM R©4-64,
Molecular Probes). Samples were spotted on 2% agarose
pads for imaging with Zeiss Axio imager Z1 fluorescence
microscope, using an EC Plan-NEOFLUAR 100× objective
(λex = 540–580 nm; λem = 593–668 nm).
Interaction of SPI009 with LPS
To assess possible interaction between SPI009 and the lipid A
compound of Gram-negative LPS layers, a whole-cell BODIPYTM
TR Cadaverine displacement assay was performed. Briefly, a late-
exponential PA14 WT culture was corrected to an OD595 of 0.3
in 50 mM Tris–HCl and added to the BODIPYTM TR Cadaverine
conjugate (BC, 5 µM; Life Technologies) in the wells of a black
microtiter plate (clear bottom). Cultures were incubated for 2 h
to allow BC binding after which equimolar amounts of Tris–
HCl (negative control), meropenem, polymyxin B and SPI009
were added and fluorescence (λex = 580 nm, λem = 620 nm)
was measured continuously for 1 h. Fluorescence values from the
negative control (Tris–HCl) were used to correct for background
fluorescence.
Antibacterial Assay
The effect of SPI009 on different bacterial cultures was assessed
as described previously (Liebens et al., 2017). Briefly, stationary
phase cultures were treated for 5 h with DMSO (carrier control)
and different concentrations of SPI009. After treatment, cultures
were washed twice in 10 mM MgSO4 and appropriate dilutions
were plated onto solid agar plates to assess the number of colony
forming units.
Generation and Whole Genome
Sequencing of SPI009-Resistant Mutants
In an attempt to generate resistant mutants, P. aeruginosa
was plated out on solid TSB agar plates containing high
concentrations of SPI009. The plates were incubated at 37◦C
for a total of 10 days but no colonies were able to grow,
proving the absence of any resistance development under the
specific conditions (our own, unpublished data). Alternatively,
resistance development was assessed using a MIC-based protocol
as previously described, with minor modifications (Briers et al.,
2014; Ling et al., 2015). An initial MIC test was performed in three
independent P. aeruginosa PA14 WT cultures with ofloxacin and
SPI009, according to EUCAST standards (EUCAST, 2003). After
24 h of growth at 37◦C, shaking, the MIC value was determined
as the minimal concentration that completely inhibited bacterial
growth. A new MIC assay was prepared using 1:100 diluted cells
at MIC/4 as a starting condition. The assay was repeated for
10 passages with daily assessment and, if necessary, adjustment
of antibiotic and compound concentrations. Intermediate and
endpoint cultures were stored at−80◦C in glycerol (25% v/v) for
further analysis. Genomic DNA of the P. aeruginosa PA14 WT
strain and the three evolved resistant mutants was isolated from
overnight cultures grown in 1/20 TSB using the DNeasy Blood
& Tissue Kit (Qiagen) following the manufacturer’s instructions.
DNA quantity and purity were verified using a NanoDrop ND-
1000, after which samples were sent to the Genomics Core Facility
of EMBL (Heidelberg, Germany) for whole genome sequencing
on the Illumina HiSeq 2500 platform. Assembly of the 125 bp
paired-end reads and further analysis was performed using CLC
Genomics Workbench v8.0. Genome sequences of the resistant
mutants were aligned with the genome of the PA14 WT strain
in order to detect genetic differences, taking into account a
coverage above 10× and cutoff frequency of 75%. Identified non-
synonymous mutations were confirmed via PCR amplification
and Sanger sequencing (GATC Biotech).
RESULTS
Genetic Analysis of the SPI009 Mode of
Action
To gain more information about the mode of action of SPI009
and allow the detection of possible persister-specific effects,
individual single-gene knockouts from a P. aeruginosa mutant
library were treated with ofloxacin alone or in combination
with SPI009 and screened for altered sensitivity to SPI009
(see overview in Supplementary Figure S1). Analysis of the
obtained screening results revealed a total of 118 and 37 different
mutants that showed an increased or decreased sensitivity
for SPI009, respectively. Functional enrichment analysis of the
sensitive mutants based on their PseudoCAP functions (Winsor
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et al., 2016), revealed an over-representation for genes involved
in “adaptation and protection” and “cell wall/LPS/capsule”
(Figure 2A and Supplementary Table S1). The relatively low
levels of resistance, combined with the functional enrichment
analysis (Figure 2A) suggest that single-gene knockouts are not
sufficient to obtain significant resistance toward the anti-persister
effects of SPI009 and point to a more general effect of the
compound.
Next, we compared genome-wide gene expression levels
of P. aeruginosa PA14 WT following treatment with either
SPI009 or an inactive analog. RNA sequencing analysis
generated a list of 297 genes that were specifically differentially
expressed (log2-fold change >1) upon treatment with SPI009
(Supplementary Table S2). Functional enrichment analysis of up-
and downregulated genes (Figure 2B), combined with network
analysis (Supplementary Figure S2) revealed a first group of
SPI009 upregulated genes to be involved in antibacterial eﬄux
and multidrug resistance, suggesting the increased efforts of the
cell to protect itself against SPI009. Another group of mostly
upregulated genes are involved in fatty acid metabolism and
degradation, suggesting altered amounts of available fatty acids
upon treatment of the cell with SPI009. Furthermore, there
is a downregulation of multiple genes involved in virulence;
including phenazine biosynthesis, pilus assembly and protein
secretion and the bacterial Type VI secretion system and biofilm
formation (Imperi et al., 2013).
Taking both genetic analyses into account, there does not
appear to be a single process or pathway that emerges as the target
for SPI009. Instead, membrane-related functions are perturbed,
supplemented with more general effects in different regulatory
and metabolic pathways. This could point to SPI009 causing
membrane damage.
SPI009 Inhibits Macromolecular
Biosynthesis in a Non-specific Manner
To further explore the hypothesis of SPI009-induced membrane
damage and rule out other bacterial mechanisms targeted by
the compound, a macromolecular synthesis assay was performed
(Cotsonas King and Wu, 2009). Addition of 17 µg/mL of SPI009
strongly reduced incorporation of radio-labeled precursors for
FIGURE 2 | Genetic analysis of SPI009 mode of action. (A) Functional enrichment of the obtained set of sensitive (black bars) and resistant (white bars) mutants
using PseudoCAP classifications. P-values were determined using a two-tailed Fisher’s exact test (α = 0.05). PseudoCAP counts represent the number of mutants in
the respective classes. (B) Functional enrichment analysis of the up- and downregulated differentially expressed genes (log2 fold change >1) as determined after
RNA sequencing upon treatment with SPI009. A two-tailed Fisher’s exact test was used to determine P-values for the classes of downregulated genes (white bars),
upregulated genes (black bars), and the total set (gray bars).
Frontiers in Microbiology | www.frontiersin.org 5 February 2018 | Volume 9 | Article 129
fmicb-09-00129 February 6, 2018 Time: 18:3 # 6
Defraine et al. SPI009 Induces Extensive Membrane Damage
DNA, RNA, proteins, fatty acids, and peptidoglycan, resulting in
a more than 50% decrease in synthesis for all macromolecules
tested (Figure 3). When compared to different antibiotics,
known to inhibit incorporation of precursors, 1/3× MIC
concentrations of SPI009 show a generally stronger inhibitory
effect, a pattern previously reported for membrane-damaging
compounds (Hobbs et al., 2008; Nowakowska et al., 2013;
Masschelein et al., 2015; Gerits et al., 2016).
SPI009 Is Capable of Disrupting Artificial
Bacterial Bilayers
To further confirm the suggested membrane damaging effect
of SPI009, its capacity to disrupt lipid bilayers that mimic
the Gram-negative inner membrane was tested. Increasing
concentrations of SPI009 clearly induced CF leakage in a
concentration-dependent manner, while the inactive analog
SPI005, displaying no antibacterial or anti-persister effect, and the
conventional antibiotic ofloxacin, did not cause any significant
leakage (Figure 4). When comparing SPI009 with the membrane
damaging antibiotic polymyxin B, 50% CF leakage was obtained
at concentrations of 11.92 ± 0.07 and 1.16 ± 0.04 µg/mL,
representing 0.185× MIC and 1.85× MIC concentrations of
SPI009 and polymyxin B (Supplementary Figure S3), respectively.
These results indicate that SPI009 is indeed capable of effectively
disturbing an artificial lipid bilayer and further support the
membrane-damaging hypothesis.
FIGURE 3 | SPI009 inhibits macromolecular synthesis. Incorporation of
[methyl-3H]-thymidine (DNA), [5,6-3H]-uridine (RNA), L-(4,5-3H)-leucine
(protein), D-[6-3H(N)]-glucosamine (peptidoglycan), 2-3H-glycerol (fatty acids)
by P. aeruginosa PA14 WT after treatment with relevant control antibiotics at
8× MIC concentrations or 17 µg/mL of SPI009. Incorporation was measured
after 30 min and expressed relative to an untreated control. Bars represent the
average of at least three independent repeats ± SEM. Statistical analysis was
performed on “counts per minute” obtained upon radioactivity detection after
treatment of the bacterial cells with MQ (untreated control), the control
antibiotic or 17 µg/mL SPI009. One-way ANOVA (α = 0.05) with appropriate
correction for multiple testing was used to determine statistically relevant
differences between the untreated control and antibiotic or untreated control
and SPI009 treatment. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
FIGURE 4 | SPI009 causes extensive CF leakage. SUVs were treated for
15 min with increasing concentrations (x-axis) of SPI009 (open circles) or the
inactive analog SPI005 (open squares). Increasing concentrations of ofloxacin,
used as a negative control, did not result in any CF leakage (data not shown).
% CF leakage was determined by fluorescence measurements, corrected for
background fluorescence and expressed relative to the positive control (0.5%
Triton X-100). Data points represent the mean of three independent
repeats ± SEM.
Membrane Permeabilization Studies
To evaluate membrane disruption activity of SPI009 on whole
P. aeruginosa cells, NPN and SYTOX Green assays were
carried out, allowing the investigation of respectively outer
and inner membrane permeabilization. SYTOX Green shows
a strong increase in fluorescence upon binding to DNA.
This is, however, only possible when the inner membrane
of the cell is compromised, thus correlating the observed
fluorescence with the amount of inner membrane damage (Roth
et al., 1997). Thirty-minute treatment of P. aeruginosa with
increasing concentrations of SPI009 caused a strong increase in
fluorescence as compared to the untreated control (Figure 5A
and Supplementary Figure S4A). At concentrations of 17 µg/mL
(= 0.33×MIC), the observed membrane damage was comparable
to the effect of treatment with 1×MIC concentrations of melittin,
the active compound in bee venom known to induce inner
membrane damage (Raghuraman and Chattopadhyay, 2007).
Next, permeabilization of the outer membrane was assessed by
means of the hydrophobic fluorescent probe NPN. Bacterial cells
normally exclude NPN. Consequently, increasing fluorescence
caused by the insertion of the probe in the phospholipid bilayer is
indicative of damage to the bacterial outer membrane (Helander
and Mattila-Sandholm, 2000). Fluorescence measurements
revealed a rapid outer membrane permeabilization by SPI009
in a clear concentration-dependent manner (Figure 5B and
Supplementary Figure S4B). In comparison, treatment with
1×MIC concentration of polymyxin B resulted in a comparable
fluorescence level at 1/6× MIC concentrations of SPI009. These
results strongly support the hypothesis that SPI009 is capable of
disrupting the bacterial membrane, and this for both the inner
and outer membrane of P. aeruginosa.
Microscopic Confirmation of Membrane
Damage
Since the bacterial membrane is such a critical part of the
cell’s architecture, membrane stains are commonly used
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FIGURE 5 | SPI009 extensively permeabilizes both inner and outer membrane of P. aeruginosa. (A) Effect of increasing concentrations of SPI009 on the inner
membrane permeability, as measured by the SYTOX Green uptake assay. Cells were treated for 30 min using melittin (Mel; 1× MIC) as a positive control.
(B) Outer membrane permeability after treatment with increasing concentrations of SPI009, using polymyxin B (PMB, 1× MIC) as a positive control. Data for both
assays represent the mean of at least three independent repeats ± SEM. Statistical comparisons with the untreated control were performed using a one-way
ANOVA (α = 0.05) with Dunnett’s correction for multiple comparison (∗P < 0.05, ∗∗P < 0.01, ∗∗∗∗P < 0.0001).
FIGURE 6 | Microscopic confirmation of SPI009 induced membrane damage. Overnight cultures of (A) P. aeruginosa and (B) S. aureus cultures were treated for
20 min with 1% DMSO (carrier control) or 34 µg/mL of SPI009. Treated cells were stained with 10 µg/mL of FM R© 4-64 and visualized using a Zeiss Axio imager Z1
fluorescence microscope equipped with an EC Plan-NEOFLUAR 100× objective (λex = 540–580 nm; λem = 593–668 nm). Scale bars correspond to 2 µM. Pictures
are representatives of repeated experiments.
for microscopic visualization of cell integrity. Treatment
of P. aeruginosa and S. aureus with DMSO (1%, carrier
control) resulted in uniformly stained membranes while
addition of 34 µg/mL SPI009 induced brightly fluorescent
membrane accumulations (Figure 6). In the Gram-negative
P. aeruginosa, a second phenotype was visible: stained
membrane blebs, possibly originating from severe outer
membrane deformations (Kulp and Kuehn, 2010). The
observed membrane accumulations after treatment with
SPI009 confirm a direct effect of the compound on the
bacterial membrane for both Gram-negative and Gram-positive
species.
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SPI009 Interacts with the Lipid A
Compound of the Bacterial LPS Layer
The BODIPYTM-TR-cadaverine probe (BC) was used to reveal
possible interactions of SPI009 with the bacterial LPS layer.
If compounds are added that have the ability to bind lipid
A, BODIPYTM-TR Cadaverine will be displaced, resulting in a
strong increase in fluorescence (Torrent et al., 2008; Gerits et al.,
2016). Positive and negative controls consisted of, respectively,
polymyxin B, known to use the interaction with lipid A for
self-promoted uptake and resulting in cell lysis (Yu et al.,
2015), and meropenem, not capable of interacting with LPS.
Comparison of the effects of equimolar amounts of SPI009 and
these controls demonstrated a clear time and concentration-
dependent interaction between SPI009 and lipid A (Figure 7).
However, since it was previously shown that SPI009 maintains its
antibacterial and anti-persister activity in Gram-positive bacteria,
the interaction with lipid A in the bacterial LPS layer cannot be
the sole mechanism of SPI009-induced membrane damage.
The Role of Efflux Pumps in SPI009
Activity
The SPI009-induced inner membrane damage, as indicated by
the SYTOX Green uptake assay, could be a secondary effect
resulting from extensive outer membrane damage caused by
SPI009. Alternatively, the compound may enter the bacterial
cell and cause membrane damage from within. To explore
these possibilities, different eﬄux mutants were evaluated for
their sensitivity toward SPI009 (Figure 8 and Supplementary
Figure S5). Upon treatment with SPI009, the PAO1-derived
YM64 mutant, lacking the four major mex operons of
P. aeruginosa; mexAB-oprM, mexCD-oprJ, mexEF-oprN, and
mexXY-oprM (Morita et al., 2001), showed a significantly
decreased survival for all concentrations tested. Treatment with
8.5, 17, and 34 µg/mL SPI009 caused significant 2.0 ± 0.3,
4.5 ± 0.9, and 3.7 ± 0.4 log unit decreases in survival as
compared to the YM WT, respectively, while 68 µg/mL of SPI009
was capable of completely eradicating the eﬄux mutant. To
further explore the role of the different eﬄux pumps missing
FIGURE 7 | SPI009 interacts with the LPS layer. BC bound P. aeruginosa
cultures were treated with equimolar amounts of SPI009, polymyxin B (positive
control; PMB) and meropenem (negative control; MEM). Fluorescence was
measured continuously, using λex = 580 nm and λem = 620 nm, and
corrected for background fluorescence. Results represent the average of four
independent repeats ± SEM with BC fluorescence values obtained after 1 h.
FIGURE 8 | Activity of SPI009 in efflux mutants. P. aeruginosa efflux mutants
YM64, 1mexCD-oprJ and 1mexXY, together with their WT strain YM, were
treated for 5 h with increasing concentrations of SPI009. Significant
differences in sensitivity toward SPI009 between the WT and different mutants
were detected using multiple t-tests (α = 0.05) with Holm–Sidak correction for
multiple comparisons and represented by ∗P < 0.05; ∗∗∗P ≤ 0.001; and
∗∗∗∗P < 0.0001. Values represent the average of at least three independent
repeats with error bars depicting SEM values. ND, not detected.
in YM64, separate 1mexCD-oprJ and 1mexXY mutants were
also analyzed. For these, only the 1mexCD-oprJ strain showed
decreased survival compared to the YM WT after treatment with
34 µg/mL SPI009. The obtained results clearly show that some
P. aeruginosa eﬄux pumps, including MexCD-OprJ, are capable
of actively removing SPI009 from the bacterial cell and suggest
the involvement of other Mex pumps, most likely not MexXY-
OprM. These experiments confirm the inner membrane as an
important target of SPI009, in addition to the observed outer
membrane permeabilization.
Role of Natural Membrane Permeability
in SPI009 Sensitivity
Since the natural membrane permeability of different bacterial
species contributes to their intrinsic antibiotic resistance
(Breidenstein et al., 2011), we investigated whether this also
affected the activity of SPI009. P. aeruginosa 1galU, is no longer
capable of synthesizing UDP-glucose, a precursor required for
the formation of the glycosyl residues found in the bacterial LPS
layer (Choudhury et al., 2005). Natural membrane permeability
was assessed by measuring NPN fluorescence of MQ-treated
samples and revealed a significantly higher permeability for
1galU (Figure 9A). Treatment with 17 or 34 µg/mL SPI009
revealed respective 1.4 ± 0.3 log and 2.9 ± 0.7 log unit decreases
in survival as compared to the WT strain.
We next wanted to evaluate the effect of SPI009 in the
complete absence of LPS. However, no P. aeruginosa strain
lacking LPS has been described to date. In contrast, a 40 nt
insertion in A. baumannii lpxC results in the complete loss of the
bacterial LPS layer without affecting viability (García-Quintanilla
et al., 2014). Moreover, like P. aeruginosa, A. baumannii is also a
member of the Pseudomonadales and an important contributor
to the spread of antibiotic resistance. As compared to the WT
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FIGURE 9 | Cells displaying increased membrane permeability show higher sensitivity toward SPI009. Mutants resulting in LPS biosynthesis malfunction or complete
loss of the LPS layer were selected for (A) P. aeruginosa and (B) Acinetobacter baumannii, respectively. Natural membrane permeability was assessed by means of
NPN assays of untreated cultures (left panel). Statistical analysis was done by means of a single unpaired, two-tailed t-test (α = 0.05). Next, stationary phase cultures
of WT and mutant strains were treated for 5 h with increasing concentrations of SPI009 (right panel). Statistical analysis was done by means of multiple t-tests
(α = 0.05) to compare the antibacterial effect of SPI009 between the WT and mutant strain, with Holm–Sidak correction for multiple testing. Displayed data points
show the average of at least three independent repeats ± SEM. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; and ∗∗∗∗P ≤ 0.0001; ND, not detected.
strain Ab-84, the absence of the LPS layer greatly increased
the observed natural membrane permeability (Figure 9B). The
differential sensitivity of these strains for SPI009 shows a more
pronounced character than for P. aeruginosa since treatment
with 17 µg/mL of SPI009 already completely eradicated the
LPS-deficient Ab-84R strain. Together, these results indicate
that the structure of the bacterial LPS layer, which partly
determines membrane integrity and strength, strongly influences
the susceptibility of the cell toward SPI009.
Generation and Analysis of
SPI009-Resistant Mutants
Being so far unable to generate spontaneous SPI009-resistant
mutants on solid growth medium (our own, unpublished data),
an evolution experiment using the MIC broth dilution method
was used to generate mutants showing a 10-fold increase in the
SPI009 MIC. MIC values slowly increased for the strains grown
in the presence of SPI009 while resistance to the conventional
antibiotic ofloxacin showed a more abrupt transition with a
first plateau of 16-fold increase in MIC being reached after
just 2 days (Supplementary Figure S6A). The results obtained
for ofloxacin are in agreement with previous fluoroquinolone
resistance evolution experiments (Wong et al., 2012; Briers et al.,
2014; Ling et al., 2015). Decreased sensitivity for SPI009 of the
evolved strains was confirmed via MIC and plate assays, where
treatment with 68 µg/mL of SPI009 caused a maximal 1.46 log
decrease in the number of surviving cells (Supplementary Figure
S6B). Whole genome sequencing and analysis of the evolved
strains revealed two identical non-synonymous SNPs in each of
the parallel lines. A first mutation involved a 47A > C change in
PA14_08120 (PA0625), a phage tail length determination protein
located in the outer membrane or outer membrane vesicles
(Choi et al., 2011; Winsor et al., 2016). PA0625 is part of a
16-ORF gene cluster coding for R-type phage tail-like pyocins
in P. aeruginosa, bacteria-produced bacteriocins that are capable
of depolarizing the cytoplasmic membrane in sensitive cells and
inhibiting active transport (Nakayama et al., 2000; Ghequire
and De Mot, 2014; Choudhary et al., 2015). A second SNP,
88G > A, was identified in nfxB, the negative regulator of the
MexCD-OprJ eﬄux system. Interestingly, this SNP is located in a
predicted helix-turn-helix region responsible for DNA-binding.
Other similar mutations in this region have been shown to
disturb the binding to the MexCD-OprJ promotor and thus
cause overexpression of this eﬄux pump and active expulsion of
SPI009 from the cell (Okazaki and Hirai, 1992; Purssell and Poole,
2013).
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A transposon mutant of nfxB showed a significant decrease in
sensitivity toward SPI009 resulting in 1.7 ± 0.4 and 3.1 ± 0.9 log
unit increases in survival as compared to the WT after treatment
with 17 and 34 µg/mL of SPI009, respectively (Supplementary
Figure S6B). In contrast to the whole genome sequencing results,
full gene knockout of PA14_08120 did not cause a significant
increase in survival. Taken together, these results confirm the
hypothesis that the MexCD-OprJ eﬄux is capable of protecting
the cell against SPI009-mediated membrane damage. Further
research will, however, be necessary to unravel the exact role of
PA14_08120 in this mechanism.
DISCUSSION
Increased understanding of persister formation mechanisms
and the general acknowledgment of their clinical importance
has resulted in a growing number of reports on anti-persister
molecules, contributing to potential future treatment options in
the fight against bacterial infections (Wood, 2015; Van den Bergh
et al., 2017). Targeting persisters is likely to greatly improve
patient outcomes but unfortunately the rational target-based
design of anti-persister therapies remains a great challenge.
Contributing to this are the limited numbers of persister cells,
the incomplete knowledge and redundancy in mechanisms
controlling persister formation and the observation that these
processes are often species-specific (Harms et al., 2016; Michiels
et al., 2016; Van den Bergh et al., 2017). A possible way
of bypassing these issues is the use of well-designed whole-
cell screenings that can identify novel compounds based on
anti-persister activity rather than target (Coates et al., 2002).
We recently reported the use of such a screening in the
identification of SPI009 (1-((2,4-dichlorophenethyl)amino)-3-
phenoxypropan-2-ol) (Liebens et al., 2017), a small molecule
capable of directly killing persister cells of clinically relevant
Gram-negative and Gram-positive pathogens in different in vitro
and in vivo set-ups. Other anti-persister compounds reported to
directly kill bacterial persister cells use varying strategies such
as depolarization and destruction of the cell membrane, DNA
cross-linking, inhibition of essential enzymes, and generation of
reactive oxygen species (Helaine and Kugelberg, 2014; Wood,
2015; Van den Bergh et al., 2017). Several characteristics of
SPI009, such as its broad-spectrum activity, ability to tackle
both dividing and non-dividing cells and the potentiation of
mechanistically different antibiotics presented a first indication
of a non-specific target. Identifying the mechanism of action for
this novel anti-persister and antibacterial compound is not only
important for the further development of possible therapies but
also increases our knowledge about persister cells and contributes
to the identification of possible targets for future anti-persister
therapies (Terstappen et al., 2007).
In this study, we present the detailed exploration of the
mode of action of SPI009, combining complementary genetic
and cellular approaches. Several lines of evidence support that
SPI009 kills persister and non-persister cells by causing extensive
membrane damage. The overall inhibition of macromolecular
synthesis at relatively low concentrations of SPI009, together
with the obtained genetic data, provided us with the indication
that SPI009 induced membrane damage (Hobbs et al., 2008;
Nowakowska et al., 2013; Masschelein et al., 2015; Gerits
et al., 2016). Several membrane and whole-cell-based assays
confirmed this hypothesis and revealed the possibility of SPI009
to efficiently and extensively damage both the outer and inner
bacterial membrane. Furthermore, microscopic analysis revealed
membrane damage and severe outer membrane deformations
and blebs in P. aeruginosa. The observed changes upon treatment
of the Gram-positive S. aureus suggest a similar mechanism
of membrane damage, but further research will be necessary
to confirm this. Since the integrity of the bacterial membrane
remains crucial for the viability of persister cells, membranes have
previously been suggested as potential targets for anti-persister
strategies (Hurdle et al., 2011). Several anti-persister compounds
described in literature, such as the Artilysin R© Art-175 (Briers
et al., 2014; Defraine et al., 2016), membrane-acting peptides
(Chen et al., 2011), HT61 (Hu et al., 2010; Hubbard et al., 2017),
and AM-0016 (Zou et al., 2013) use this strategy to efficiently
tackle antibiotic-tolerant persister cells of both Gram-negative
and Gram-positive species.
Although SPI009 proved capable of interacting with the lipid
A moiety of the bacterial LPS layer, the demonstrated activity in
Gram-positive species and LPS-deficient strains exclude LPS as
the primary binding target of SPI009. However, the architecture
of the LPS layer and resulting membrane permeability do have a
strong influence on SPI009 activity. Possible explanations include
the physical barrier formed by the LPS sugars, its influence
on overall membrane strength or the changes in membrane
charge due to the absence or presence of sugars and phosphate
groups (Rana et al., 1991; Papo and Shai, 2005). Additionally, the
increased SPI009 sensitivity of the P. aeruginosa YM64 mutant,
lacking the four major Mex eﬄux pumps (Morita et al., 2001)
and resulting in increased intracellular concentrations of the
compound, provided evidence that SPI009 can cause cytoplasmic
membrane damage and suggests the possible use of eﬄux pump
inhibitors to further increase SPI009 activity.
Additional experiments revealed a possible role for MexCD-
OprJ in the eﬄux of SPI009, but the substantial difference
in sensitivity between YM64 and 1mexCD-oprJ suggests that
additional eﬄux mechanisms are involved. Interestingly, both the
genetic screen and RNA sequencing revealed genes belonging
to the mexCD-oprJ system and its regulator nfxB, previously
reported to be inducible by membrane-damaging agents and best
known for its role in fluoroquinolone resistance (Morita, 2003;
Fraud et al., 2008; Purssell and Poole, 2013). Besides increasing
the eﬄux of antibacterial compounds through MexCD-OprJ,
1nfxB also influences cell membrane permeability (Okazaki and
Hirai, 1992), thus suggesting an alternative role for nfxB in
SPI009 resistance. The involvement of this bacterial eﬄux pump
was corroborated through genetic analysis of the evolved SPI009-
resistant strains, where all three independent mutants showed
SNPs in nfxB and PA14_08120. While inactivation of nfxB
strongly decreased sensitivity toward SPI009, this was not the case
for PA14_08120. The R2 region of P. aeruginosa has previously
been linked with antibiotic resistance. Fluoroquinolone induced
production and release of pyocins was shown to cause cell lysis,
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while deletion of several R2 genes induced significant resistance
to ciprofloxacin (Brazas and Hancock, 2005; Breidenstein et al.,
2008). However, the lack of upregulation of any of the R2
genes in response to SPI009 (see Supplementary Table S2),
suggests a different role for PA14_08120 in SPI009 susceptibility.
Differences in survival between the nfxB knockout mutant and
the SPI009-resistant strains could suggest the enhancement of the
observed SPI009 resistance after accumulation of both mutations.
The absence of SPI009 resistant mutants in earlier attempts,
combined with the lack of any clear resistance phenotypes
after single-gene knockout, predicted fitness defects of 1nfxB
(Stickland et al., 2010) and possibility of using eﬄux pump
inhibitors (Lomovskaya and Watkins, 2001) all decrease the
chances of SPI009 resistance emerging in in vivo situations.
Overall, the use of different combined approaches resulted
in compelling evidence that the novel antibacterial compound
SPI009 is capable of directly killing P. aeruginosa cells as a
consequence of severe membrane damage. Further experiments
revealed the ability of the compound to impair both the
outer and inner membrane of P. aeruginosa, the latter being a
direct consequence of SPI009 entry into the cell. The crucial
importance of membrane integrity for survival of both active
and metabolically inactive bacterial cells combined with the
suggested limited resistance potential of membrane-damaging
compounds (Hurdle et al., 2011) and the previously reported
limited cytotoxicity (Liebens et al., 2017), further support the
clinical potential of SPI009 and its role as a scaffold in the
development of future anti-persister therapies.
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